Levamisole (LEV) is a drug with a dual career. Originally introduced as an anthelminthic
agent in the mid-1960s, it soon revealed itself as a compound capable of increasing …

Levamisole is of interest to immunopharmacologists because it has been shown to influence
host defence. In this short article the author will concentrate on other aspects of levamisole …

The clinical need for therapeutic agents designed to augment immune responsiveness in
patients with deficient or depressed resistance has led to an increased interest in cellular …

Levamisole, a simple chemical first introduced as a broad spectrum anthelmintic, is an
immunotherapeutic compound with anti-anergic properties. The present work summarizes …

The need for treatments to correct an immunological defect, or to restore an impaired
immune response associated with disease or ageing, has led to the development of …

Levamisole, a simple synthetic chemical, was first introduced as an anthelmintic in human
and veterinary medicine. The drug is the first member of a potential new class of …

Levamisole, an anthelmintic discovered in the 1960s, was serendipitously found to have
immunomodulating effects in 1971, when it was shown to enhance the protective effect of a …

Levamisole has been used in a wide array of clinical research and treatment settings over
the past two decades, ranging from such diseases as helminthic infestations to various …

Levamisole is a synthetic, orally active immunomodifier. Although it does not generally
influence normal immune reactivity, it is capable of restoring to normal levels depressed …

The major features of levamisole immunotherapy are distilled from experiences gained so
far. The biochemical effects of levamisole are discussed in view of its effects on T …